BOSTON Program

Breath Therapeutics' lead program, BOSTON, develops the first therapy for the treatment of Bronchiolitis Obliterans Syndrome (BOS), which is a life-threatening disease where the immune system attacks the airways of the lungs.

  • BOS is the result of a injury, some known and some unknown, that progresses even when the injury is removed.

  • Histopathology of airways affected by BOS show a T-cell mediated inflammatory process that results in fibrous scarring of the respiratory bronchioles.
Barker et al., NEJM 2014; 370:1820-8
Barker et al., NEJM 2014; 370:1820-8
Unmet Medical Need

BOS is devastating to lung transplant and allogeneic stem cell recipients. There is no known therapy.

  • BOS is irreversible and rapidly progressive. Mostly it leads to respiratory failure and death within 9-24 months after diagnosis.

  • BOS is the leading cause of death following lung transplantation. Half of all lung transplant recipients die within 5 years and BOS is the #1 reason.
Drug-Device Combination

Liposomal Cyclosporine A (L-CsA) for inhalation targets the site of BOS-related airway inflammation.

  • Proprietary drug formulation
  • High topical drug concentrations at the site of action with without increasing systemic toxicity
  • Orphan Drug Designation (FDA and EMA)
  • PARI Investigational eFlow® nebulizer system for L-CsA with world-wide exclusive rights
  • Multiple layers of IP protection for drug & device
L-CsA, Liposomal Cyclosporine A Formulation
L-CsA, Liposomal Cyclosporine A Formulation
eFlow®, aerosol nebulizer “L-CsA version”
eFlow®, aerosol nebulizer “L-CsA version”